SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/292799"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/292799" > Addition of the cal...

Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential hypertension.

Dahlöf, Björn, 1953 (författare)
Gothenburg University,Göteborgs universitet,Medicinska institutionen,Department medicine
Andrén, Lennart, 1946 (författare)
Gothenburg University,Göteborgs universitet,Medicinska institutionen,Department medicine
Eggertsen, Robert, 1948 (författare)
Gothenburg University,Göteborgs universitet,Medicinska institutionen,Department medicine
visa fler...
Jern, Sverker, 1954 (författare)
Gothenburg University,Göteborgs universitet,Medicinska institutionen,Department medicine
SVensson, Anders (författare)
Gothenburg University,Göteborgs universitet,Medicinska institutionen,Department medicine
Sievert, A (författare)
Gothenburg University,Göteborgs universitet,Medicinska institutionen,Department medicine
Aurell, Mattias, 1934 (författare)
Gothenburg University,Göteborgs universitet,Medicinska institutionen,Department medicine
Hansson, Lennart (författare)
Gothenburg University,Göteborgs universitet,Medicinska institutionen,Department medicine
visa färre...
 (creator_code:org_t)
1987
1987
Engelska.
Ingår i: Journal of cardiovascular pharmacology. - 0160-2446. ; 10 Suppl 10, s. S102-4
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Several large-scale studies have recently drawn attention to the fact that arterial hypertension frequently is inadequately controlled and that therapeutic alternatives other than the commonly employed stepped-care treatment may be needed in order to obtain normotension. For this reason PN 200-110, a new dihydropyridine calcium antagonist--at two different dose levels (average 3.8 mg b.i.d. or 5.7 mg b.i.d.)--or placebo was added in a double-blind cross-over trial to pindolol, 10 mg per day, in 20 patients with essential hypertension, after an initial 3-week placebo period. Ionized calcium in serum was determined repeatedly during the study. From an initial level of 157/100 mm Hg, PN 200-110 at the first dose level reduced blood pressure by 14/11 mm Hg (p less than 0.01/0.001) and at the second dose level reduced blood pressure by 22/18 mm Hg (p less than 0.001/0.001). The reduction in mean arterial pressure was significantly correlated to age (=0.050, p less than 0.05). There was no significant increase in heart rate, nor were there any significant correlations between ionized calcium and the effect of PN 200-110 nor between the changes in ionized calcium and the changes in blood pressure. Adverse effects were few and mild. One patient had to be withdrawn because of side effects, probably not related to the investigated drugs. Thus, addition of PN 200-110 to hypertensive patients treated with pindolol caused highly significant and clinically relevant further reductions in arterial pressure. The results show that a combination of this kind offers the possibility of good blood pressure control.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Allmänmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- General Practice (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Adult
Aged
Blood Pressure
Calcium
blood
Calcium Channel Blockers
therapeutic use
Double-Blind Method
Drug Therapy
Combination
Female
Heart Rate
Humans
Hypertension
drug therapy
physiopathology
Isradipine
Male
Middle Aged
Oxadiazoles
therapeutic use
Pindolol
therapeutic use
Random Allocation

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy